Business
CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025
BERKELEY HEIGHTS, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing
About this update from Cormedix Inc.
BERKELEY HEIGHTS, N.J. , March 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024 , before the market opens on Tuesday, March 25, 2025 , and will host a corporate update conference call at 8:30am Eastern Time . Tuesday, March 25 th @ 8:30am ET Domestic: 1-844-481-2557 International: 1-412-317-0561 Conference ID: 10197392 Webcast: Webcast Link About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023 . CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024 . CorMedix is commencing clinical studies in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis (HD) patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other therapeutic areas. For more information visit: www.cormedix.com . Investor Contact: Dan Ferry Managing Director LifeSci Advisors [email protected] (617) 430-7576 Source: CorMedix, Inc.